Type 2 diabetes articles for people who want clear, practical guidance on symptoms, diagnosis, blood sugar targets, medicines, food, activity, and long-term risk reduction.Start here for plain-language explainers, safety notes, and care-team questions. Use this information to prepare for conversations with a clinician, not to change prescribed treatment on your own.
A 40-week randomized trial found that semaglutide added to reduced insulin glargine improved HbA1c and weight compared with titrated insulin alone, but gastrointestinal side effects were more common.
A 15,413-person real-world study linked publicly funded flash glucose monitoring with fewer acute diabetes-related hospitalizations, shorter stays, and lower inpatient costs, but its quasi-experimental design cannot prove that monitoring alone caused the improvements.
A post hoc CANVAS analysis found no clear kidney or cardiovascular advantage for canagliflozin 300 mg over 100 mg, but the findings are hypothesis-generating rather than definitive.
A prespecified VESALIUS-CV analysis found fewer major cardiovascular events with evolocumab in selected adults with high-risk diabetes, but the results are not a recommendation for everyone with diabetes.
A randomized trial found that automated insulin delivery improved time in range for adults with diabetes and advanced kidney disease, but long-term benefits remain unknown.
The ATTEMPT study found early kidney changes under carefully monitored research conditions, but it does not prove long-term kidney protection or routine use in type 1 diabetes.
A randomized trial found that home-delivered medically tailored groceries improved HbA1c and food security for some Medicaid-insured adults with type 2 diabetes.
A safety update describes a rare eye disorder reported with GLP-1 medicines. Here is what people with diabetes should know about symptoms, uncertainty and urgent care.
BMI remains useful, but new obesity frameworks encourage clinicians to also consider waist-based measurements, health complications, and daily function when assessing people with diabetes.
Recent case reports have raised a rare but serious safety question involving semaglutide, poor intake, rapid weight loss, thiamine deficiency, and neurological symptoms. The evidence shows an association, not proven causation.
